https://thedigestlab.com/press-releases/us-fda-approves-rybrevant-fasprotm-amivantamab-and-hyaluronidase-lpuj-co-formulated-withThe Digest Laben2026-11-06T15:21:42.336ZU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer https://thedigestlab.com/press-releases/johnson-and-johnson-announces-us-fda-approval-of-rybrevant-fasprotm-amivantamab-andThe Digest Laben2026-11-06T02:14:41.787ZJohnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer https://thedigestlab.com/press-releases/lantheus-holdings-incThe Digest Laben2026-11-05T13:04:59.970ZLantheus Holdings, Inc. https://thedigestlab.com/press-releases/lilly-to-showcase-new-retatrutide-taltz-ixekizumab-and-zepbound-tirzepatide-data-at-acrThe Digest Laben2026-11-05T11:53:20.761ZLilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity